Cardiac Tissue Engineering: Implications for Pediatric Heart Surgery

Zimmermann, Wolfram‐Hubertus; Cesnjevar, Robert

doi:10.1007/s00246-009-9405-6

Cited by 65 publications

(41 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, one characteristic of heart and skeletal muscle is the presence of red colored oxygen-binding myoglobin. Many tissue engineered cardiac tissue protocols derive force-producing cells with the proper stimulatory cues, that are, however, clearly not red, even when derived from fetal tissue [104,106]. A similar observation of lack of proper gross morphology was made clear in a recent chapter discussing an engineered liver [104].…”

Section: Specific Mitochondrial Needs In Bioengineered Tissues From Pmentioning

confidence: 83%

From Oocytes and Pluripotent Stem Cells to Fully Differentiated Fates: (Also) a Mitochondrial Odyssey

Ramalho‐Santos

Rodrigues

2012

Mitochondrial DNA, Mitochondria, Disease and Stem Cells

View full text Add to dashboard Cite

In the pluripotent cellular state, characteristic of preimplantation embryos and embryonic stem cells (ESCs), metabolic activity in general, and mitochondrial function in particular, seems to be subdued; increasing upon differentiation, possibly to avoid oxidative stress-mediated damage. A crucial but overlooked aspect of development is related to how mitochondrial differentiation follows somatic differentiation in terms of producing specific cell fates with very distinct metabolic profiles and energy requirements, notably in two of the most sought after cell fates in the field of regenerative medicine, the neuronal and muscular lineages. Finally, recent evidence suggests that, although induced pluripotent stem (iPS) cells obtained from somatic cells show hallmarks of pluripotency from a mitochondrial standpoint, these characteristics are not as pronounced as those shown by ESCs. Thus, incomplete reprograming might also be reflected in terms of iPS mitochondrial status, with possible implications for the derivation of patient-specific cells.

show abstract

Section: Specific Mitochondrial Needs In Bioengineered Tissues From Pmentioning

confidence: 83%

From Oocytes and Pluripotent Stem Cells to Fully Differentiated Fates: (Also) a Mitochondrial Odyssey

Ramalho‐Santos

Rodrigues

2012

Mitochondrial DNA, Mitochondria, Disease and Stem Cells

View full text Add to dashboard Cite

show abstract

“…Apart from MI, congenital malformations exist where ventricular or atrial muscle is lacking (Zimmermann and Cesnjevar, 2009). The application of donor cardiomyocytes and cardiac tissue engineering for improving congenital heart defects or malformations has been recently reviewed (Choi et al, 2011;Zimmermann and Cesnjevar, 2009).…”

Section: -Heart Disease and Cell Therapymentioning

confidence: 99%

“…The application of donor cardiomyocytes and cardiac tissue engineering for improving congenital heart defects or malformations has been recently reviewed (Choi et al, 2011;Zimmermann and Cesnjevar, 2009). Children with malformations, such as severe ventricular malformations, have limited treatment options, with heart transplantation being one of the only possibilities (Conway and Dipchand, 2010).…”

Section: -Heart Disease and Cell Therapymentioning

confidence: 99%

See 1 more Smart Citation

Cardiac Tissue Engineering

Momtahan

Castleton

Ford

et al. 2014

Methods in Molecular Biology

View full text Add to dashboard Cite

The limited treatment options available for heart disease patients has lead to increased interest in the development of embryonic stem cell (ESC) therapies to replace heart muscle. The challenges of developing usable ESC therapeutic strategies are associated with the limited ability to obtain a pure, defined population of differentiated cardiomyocytes, and the design of in vivo cell delivery platforms to minimize cardiomyocyte loss. These challenges were addressed in Chapter 2 by designing a cardiomyocyte selectable progenitor cell line that permitted evaluation of a collagen- iii and function. Notably, no significant differences in cell survival, cardiac phenotype, and cardiomyocyte function were detected with the addition of the RGD domain to the collagen scaffold. Thus, in summary, these three studies have resulted in the identification of a potential cell surface marker for ESC-derived cardiomyocyte purification, and prove that collagen-based scaffolds can sustain ES-cardiomyocyte growth and function. This has set the framework for further studies that will move the field closer to obtaining a safe and effective delivery strategy for transplanting ESCs onto human hearts.

show abstract

“…The cell sheet approach consists of superposing several monolayers of cultured myocytes, which then generate compact muscular tissues [20].…”

Section: The Challenge Of Tissue and Organ Engineeringmentioning

confidence: 99%

General Overview of the Seventh International Symposium on Stem Cell Therapy and Cardiovascular Innovations

Gutiérrez

Sanz‐Ruiz

Alvarez

et al. 2010

J. of Cardiovasc. Trans. Res.

View full text Add to dashboard Cite

The Seventh International Symposium on Stem Cell Therapy and Cardiovascular Innovations was held in Madrid on the 6th and 7th of May 2010. Gathering for the seventh consecutive year the most relevant researchers and opinion leaders on cardiovascular cell therapy, it has become the most important worldwide event on this field. A comprehensive review of the last developments on cell therapy, surgery for heart failure and tissue engineering was made, and the results of three clinical trials were reported. The Symposium was dedicated to the memory of Professor Helmut Drexler.

show abstract

Cardiac Tissue Engineering: Implications for Pediatric Heart Surgery

Cited by 65 publications

References 64 publications

From Oocytes and Pluripotent Stem Cells to Fully Differentiated Fates: (Also) a Mitochondrial Odyssey

From Oocytes and Pluripotent Stem Cells to Fully Differentiated Fates: (Also) a Mitochondrial Odyssey

Cardiac Tissue Engineering

General Overview of the Seventh International Symposium on Stem Cell Therapy and Cardiovascular Innovations

Contact Info

Product

Resources

About